UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis

Calafato, MS; Austin-Zimmerman, I; Thygesen, JH; Sairam, M; Metastasio, A; Marston, L; Abad-Santos, F; ... Bramon, E; + view all (2020) The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis. The Pharmacogenomics Journal 10.1038/s41397-019-0142-9. (In press).

[img] Text (Article)
Bramon_Calafato_manuscript_09Dec19.pdf - Published version
Access restricted to UCL open access staff until 5 August 2020.

Download (677kB)
[img] Text (Figures)
Bramon_Figures 1 to 4.pdf - Accepted version
Access restricted to UCL open access staff until 5 August 2020.

Download (284kB)
[img] Text (Table 1)
Bramon_Calafato_Table1_09Dec19.pdf - Accepted version
Access restricted to UCL open access staff until 5 August 2020.

Download (472kB)
[img] Text (Supplementary material)
Bramon_Calafato_supplement_09Dec19.pdf - Accepted version
Access restricted to UCL open access staff until 5 August 2020.

Download (957kB)

Abstract

Hyperprolactinemia is a known adverse drug reaction to antipsychotic treatment. Antipsychotic blood levels are influenced by cytochrome P450 enzymes, primarily CYP2D6. Variation in CYP450 genes may affect the risk of antipsychotic-induced hyperprolactinemia. We undertook a systematic review and meta-analysis to assess whether CYP2D6 functional genetic variants are associated with antipsychotic-induced hyperprolactinemia. The systematic review identified 16 relevant papers, seven of which were suitable for the meta-analysis (n = 303 participants including 134 extreme metabolisers). Participants were classified into four phenotype groups as poor, intermediate, extensive, and ultra-rapid metabolisers. A random effects meta-analysis was used and Cohen’s d calculated as the effect size for each primary study. We found no significant differences in prolactin levels between CYP2D6 metabolic groups. Current evidence does not support using CYP2D6 genotyping to reduce risk of antipsychotic-induced hyperprolactinemia. However, statistical power is limited. Future studies with larger samples and including a range of prolactin-elevating drugs are needed.

Type: Article
Title: The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis
DOI: 10.1038/s41397-019-0142-9
Publisher version: https://doi.org/10.1038/s41397-019-0142-9
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Genetics research, Pharmacogenomics
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health > Primary Care and Population Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Health Informatics
URI: https://discovery.ucl.ac.uk/id/eprint/10094014
Downloads since deposit
4Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item